Zhengye Biotechnology, Inc. is a China-based biopharmaceutical company specializing in the research, development and manufacturing of recombinant protein therapeutics and monoclonal antibodies. Since its inception, the company has focused on leveraging cutting-edge bioprocessing technologies to produce high-purity, clinical-grade biologics for the treatment of oncology, autoimmune disorders and metabolic diseases. Its portfolio encompasses a range of cytokines, growth factors, antibody fragments and full-length antibodies aimed at addressing both established and emerging therapeutic areas.
The company’s operations are anchored by state-of-the-art R&D and manufacturing facilities located in Tianjin, China, where integrated upstream and downstream production lines support both proprietary programs and contract development and manufacturing organization (CDMO) services. Zhengye Biotechnology employs advanced cell culture, purification and analytical platforms to ensure scalability and regulatory compliance, catering to global standards for investigational and commercial immunotherapies and protein drugs.
In addition to its domestic footprint, Zhengye Biotechnology has established strategic partnerships and service agreements across North America and Europe, enabling access to international clinical trial networks and regulatory pathways. Through its subsidiary in the United States and collaboration with academic institutions, the company seeks to accelerate the translation of novel biologics into late-stage clinical studies. Its global reach is further enhanced by supply chain integrations that facilitate the export of clinical and commercial products to markets in Asia, the Americas and the European Union.
The company is guided by a leadership team with extensive experience in biologics development, regulatory affairs and manufacturing scale-up. Management’s strategic priorities include advancing a pipeline of first-in-class and best-in-class candidates, expanding CDMO offerings to third-party innovators, and forging alliances that bolster its position as a full-service provider of recombinant protein therapeutics. With a commitment to innovation and quality, Zhengye Biotechnology continues to build its capabilities in next-generation biopharmaceuticals.
AI Generated. May Contain Errors.
Free ZYBT Stock Alerts